Design, synthesis, and biological evaluation of 1,2,3,7-tetrahydro-6h-purin-6-one and 3,7-dihydro-1h-purine-2,6-dione derivatives as corticotropin-releasing factor(1) receptor antagonists |
| |
Authors: | Hartz Richard A Nanda Kausik K Ingalls Charles L Ahuja Vijay T Molski Thaddeus F Zhang Ge Wong Harvey Peng Yong Kelley Michelle Lodge Nicholas J Zaczek Robert Gilligan Paul J Trainor George L |
| |
Affiliation: | Discovery Chemistry, Neuroscience Biology, and Metabolism and Pharmacokinetics, Bristol-Myers Squibb Company, Pharmaceutical Research Institute, 5 Research Parkway, Wallingford, Connecticut 06492, USA. richard.hartz@bms.com |
| |
Abstract: | A growing body of evidence suggests that CRF(1) receptor antagonism offers considerable therapeutic potential in the treatment of diseases resulting from elevated levels of CRF, such as anxiety and depression. A series of novel 1,2,3,7-tetrahydro-6H-purin-6-one and 3,7-dihydro-1H-purine-2,6-dione derivatives was synthesized and evaluated as corticotropin releasing factor-1 (CRF(1)) receptor antagonists. Compounds within this series, represented by compound 12d (IC(50) = 5.4 nM), were found to be highly potent CRF(1) receptor antagonists. In addition, compounds 12d and 12j were determined to be selective CRF(1) antagonists. The synthesis, structure-activity relationships and pharmacokinetic properties of compounds within this series is presented. |
| |
Keywords: | |
本文献已被 PubMed 等数据库收录! |
|